Download our White Paper

MIDD white_book_mockup@2x

Content of the case study


How do in silico clinical trials work?

NOVA builds disease and treatment computational models based on knowledge extracted from literature and data. To simulate a trial, we run those models on virtual patients with appropriate simulated scenarios (in silico experimental protocols) to predict the clinical efficacy of new drugs at the population level before in-human trials take place.


How do we build models?

NOVA's approach combines mathematical models of diseases and treatments with virtual patients into an integrated clinical trial simulation platform Jinkō®, in 6 stages: the problem formulation, the systemic knowledge review, the computational models, the calibration, the model validation and the simulation.


What are the applications?

NOVA’s Model-informed Drug Development (MiDD) approach yields applications spanning the entire R&D spectrum, from systematic target combination exploration to value demonstration to payers: from the discovery stage to pricing and market access.